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Abstract
Bacteria rely on two known DNA-level defenses against their bacteriophage predators: restriction-modification and
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR-associated (Cas) systems. Certain phages have
evolved countermeasures that are known to block endonucleases. For example, phage T4 not only adds hydroxymethyl
groups to all of its cytosines, but also glucosylates them, a strategy that defeats almost all restriction enzymes. We sought to
determine whether these DNA modifications can similarly impede CRISPR-based defenses. In a bioinformatics search, we
found naturally occurring CRISPR spacers that potentially target phages known to modify their DNA. Experimentally, we
show that the Cas9 nuclease from the Type II CRISPR system of Streptococcus pyogenes can overcome a variety of DNA
modifications in Escherichia coli. The levels of Cas9-mediated phage resistance to bacteriophage T4 and the mutant phage
T4 gt, which contains hydroxymethylated but not glucosylated cytosines, were comparable to phages with unmodified
cytosines, T7 and the T4-like phage RB49. Our results demonstrate that Cas9 is not impeded by N6-methyladenine, 5-
methylcytosine, 5-hydroxymethylated cytosine, or glucosylated 5-hydroxymethylated cytosine.
Citation: Yaung SJ, Esvelt KM, Church GM (2014) CRISPR/Cas9-Mediated Phage Resistance Is Not Impeded by the DNA Modifications of Phage T4. PLoS ONE 9(6):
e98811. doi:10.1371/journal.pone.0098811
Editor: Shuang-yong Xu, New England Biolabs, Inc., United States of America
Received April 7, 2014; Accepted May 7, 2014; Published June 2, 2014
Copyright:  2014 Yaung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by US Department of Energy grant DE-FG02-02ER63445 (to GMC) and the Wyss Institute for Biologically Inspired Engineering.
SJY was supported by a National Science Foundation Graduate Research Fellowship and KME by the Wyss Technology Development Fellowship. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors declare that no competing interests exist.
* E-mail: gchurch@genetics.med.harvard.edu
. These authors contributed equally to this work.
Introduction
Bacteria utilize an assortment of anti-phage defense mecha-
nisms, including two that act at the nucleic acid level: restriction-
modification and Clustered Regularly Interspaced Short Palin-
dromic Repeats (CRISPR)-CRISPR-associated (Cas) systems.
Some bacteriophages have developed extensive modifications to
their DNA that enable them to evade host restriction endonucle-
ases. For example, phage T4 replaces each cytosine with
hydroxymethylated cytosine (hmC), then glucosylates the hydro-
xymethyl group to form glucosylated hmC (ghmC) [1]. The bound
glucose shelters the phage genome from the host’s modified
cytosine restriction systems, McrA, McrBC, and Mrr, which
recognize methylcytosines and hmCs but not ghmCs [2].
CRISPR-Cas systems also function as endonucleases, though
unlike restriction enzymes, their recognition sites are programma-
ble by CRISPR RNAs (crRNAs) [3]. As an adaptive immune
system, CRISPR-Cas components incorporate fragments of DNA
from invading viruses or plasmids into arrays composed of spacers
interspersed with repeats on the genome [4,5]. In Type II
CRISPR systems, transcribed arrays are processed into crRNAs
that form a complex with the RNA-guided Cas9 nuclease and a
trans-activating RNA (tracrRNA) [6]. The crRNA guides the
complex to double-stranded DNA ‘‘protospacer’’ sequences that
match the sequence of the spacer and are flanked by a
‘‘protospacer adjacent motif’’ (PAM) unique to the CRISPR
system [7]. If spacer-protospacer base-pairing is a close match,
Cas9 cuts both strands of DNA, often eliminating the plasmid or
phage. We sought to determine whether various DNA modifica-
tions known to block restriction systems can similarly impede
CRISPR-Cas defenses.
Materials and Methods
Bioinformatics search
We derived a list of 1749 unique spacers from several sources:
49 E. coli strains with CRISPR structures in the CRISPRdb
database (http://crispr.u-psud.fr/crispr/, [8]), 72 strains in the
ECOR collection [9], 263 strains isolated from humans or animals
in various regions of France [10], and 194 Shiga toxin-producing
E. coli (STEC) strains [11]. CRISPR array sequences were
processed in CRISPRfinder (http://crispr.u-psud.fr/Server/,
[12]) to extract spacer sequences.
We performed BLASTn searches (http://blast.ncbi.nlm.nih.
gov/, [13]) with a word size of seven optimized for short sequences
and an E-value of less than 0.1, which corresponded to roughly at
least 14 matched nucleotides in the T2/T4/T6 genomes search
and at least 17 matched nucleotides in the all T4-like genomes
search. We screened hits by first looking for a concentration of
exact nucleotide matches at the 59 end, which would be consistent
with a seven-nucleotide ‘‘seed’’ region that does not tolerate
mismatches [14]. Outside the seed sequence, at least five
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mismatches are tolerated [14], though the upper limit of tolerable
mismatches has not been characterized in the E. coli CRISPR
system. We then checked for a properly oriented E. coli Type I-E
CRISPR PAM such as AAG, ATG, AGG, and GAG in the
targeted sequence.
Bacterial strains and plasmid construction
In addition to wild-type E. coli K-12 MG1655 and E. coli B, we
used methyltransferase-deficient (dam2/dcm2) E. coli K-12
(ER2925, New England Biolabs, Ipswich, MA) and restriction-
deficient (mcrA2 mcrBC2 mrr2 hsdR2) E. coli K-12 (ER1821, New
England Biolabs). E. coli were grown at 37uC in LB broth and
supplemented with antibiotics as needed at final concentrations of
100 mg/mL spectinomycin, 30 mg/mL chloramphenicol, 300 mg/
mL erythromycin, and 100 mg/mL carbenicillin.
Cells expressing SpCas9 were constructed by transforming in
DS-SPcas (Addgene plasmid 48645, [15]), which encodes SpCas9
and its cognate tracrRNA on a backbone with a cloDF13 origin of
replication and aadA gene. In the dam/dcm methylation studies,
we assembled a compatible protospacer plasmid encoding all five
of the target sequences with their PAMs; we placed the control,
dam1, and dcm1 sequences after a pBR322 origin of replication,
and the dam2 and dcm2 sequences after a bla gene. In the T7
infection assays, the spacer was expressed on DS-SPcas such that
there was no separate spacer plasmid. In all other experiments, we
maintained the designed spacer on a separate plasmid (based on
PM-SP!TB, Addgene plasmid 48650, [15]) that expressed one
spacer followed by the SpCas9 repeat on a backbone with a p15a
origin of replication and cat gene. When a different resistance
marker was needed, we switched cat with EryR.
Bacteriophage strains and propagation
Phage T7 stock was propagated in E. coli K-12 MG1655 and
RB49 stock (obtained from H. M. Krisch) propagated in E. coli B.
Wild-type T4 stock was propagated in E. coli K-12 MG1655.
Phage T4 gt (a gift from New England Biolabs) is T4 a-gt57 b-gt14,
which does not have functional a- and b-glucosyltransferases [16].
Because the E. coli restriction system recognizes and cleaves hmC,
preventing T4 gt from plaquing efficiently, we conducted all
experiments involving this phage in the restriction-deficient E. coli
K-12 host ER1821.
In phage stock preparation, an overnight bacterial host culture
was diluted 1:100 in LB, inoculated with phage, and grown for
2.5–5 hours (during which the turbidity of cultures rose and then
fell due to lysis). The lysates were spun down at 8000 x g for 5
minutes at 4uC to remove cell debris. The supernatant was filtered
through a 0.45 mM membrane and stored at 4uC.
Transformation assays
We prepared protospacer and spacer plasmids from a dam+/
dcm+ strain, NEB Turbo (New England Biolabs), and performed
transformation assays using E. coli K-12 MG1655 bacteria
containing the protospacer plasmid and DS-SPcas. After trans-
forming equimolar amounts of each spacer plasmid and selecting
for all three plasmids (DS-SPcas, protospacer, and spacer), we
quantified the number of transformants relative to a transformed
spacer plasmid that did not target the protospacer plasmid. We
also reversed the transformation order for one set of experiments;
that is, we transformed the protospacer plasmid into E. coli already
carrying DS-SPcas and each spacer plasmid. We observed
comparable numbers of transformants regardless of order. We
repeated the same transformations in methyltransferase-deficient
E. coli K-12 using equimolar unmethylated protospacer and spacer
plasmids, which were prepared from E. coli K-12 dam2/dcm2.
Again, for one set of experiments, we reversed the transformation
order and noted similar numbers of transformants.
Plaque assays and efficiency-of-plating calculations
To characterize the level of phage resistance conferred by Cas9,
we infected normalized densities of protected E. coli with equal
titers of phages and counted the number of plaques. Equal cell
densities were obtained by diluting an overnight culture and
normalizing to an OD600nm of 0.3 after several hours of growth.
We added 2 mL of phage to 120 mL of cells, mixed them
thoroughly in 1 mL of 0.6% top agar with appropriate antibiotics
within 20 minutes, and poured the mixture onto 3 mL of 1.5%
solid agar. Independent experiments were performed with
different phage dilutions. To calculate an efficiency of plating
(EOP), we divided the phage titer from plating the phage on a
protected strain by the phage titer from plating the phage on a
susceptible wild-type strain.
Results
Natural spacers target phages with modified DNA
We began by attempting to discover naturally acquired spacers
in bacteria that target phages known to contain modified DNA.
Only a handful of phage families have been identified with
completely modified DNA, including Bacillus subtilis phage PBS2,
Synechococcus elongates phage S2L, and Escherichia coli phage T4 [17].
Since CRISPR-Cas systems and phages of E. coli have been better
studied than those of the other bacterial hosts, we focused on 1749
unique E. coli spacers in available array sequences from the ECOR
collection, Shiga toxin-producing E. coli (STEC), and other
databases.
Upon searching for candidate protospacers in phages T2, T4,
and T6, all of which contain ghmC DNA [1], we found one hit
that matched 25 of 32 nucleotides in T29s gene 38, although this
spacer was only found in one human-associated E. coli (Figure 1A).
In an expanded search including T4-like phages, we identified
another hit with 29 nucleotides matching phage CC319s gp35
(Figure 1B). CC31 is the only known non-T-even type phage with
predicted glucosyltransferase genes [18], which are required for
generating ghmC from hmC. This spacer was found in many
different E. coli isolates.
The potential presence of natural spacers targeting phage with
modified DNA suggests that CRISPR-Cas systems may overcome
this form of phage defense. To test this hypothesis, we explored the
extent to which the Type II-A Streptococcus pyogenes Cas9 (SpCas9),
the most commonly used CRISPR-Cas system for genome
engineering, is able to cleave various forms of modified DNA.
Cas9 cuts N6-methyladenine and 5-methylcytosine in
E. coli
DNA adenine methyltransferase (dam) methylates the adenine
in 59-GATC-39, while DNA cytosine methyltransferase (dcm)
methylates the internal cytosine in 59-CCTGG-39 and 59-
CCAGG-39 in E. coli. We designed target sequences containing
one to two dam or dcm sites as well as a control target sequence
with no methylation sites (Figure 2A). We prepared spacer and
protospacer plasmids from a dam+/dcm+ strain and selected for
the coexistence of each spacer and its targeted protospacer in
transformation assays using dam+/dcm+ cells expressing SpCas9.
All targeted sequences yielded 102 to 103 fewer transformants than
the non-targeted control regardless of whether they contained dam
or dcm methylation sites (Figure 2B). We observed similar values
in methyltransferase-deficient (dam2/dcm2) E. coli K-12, in which
all plasmids were prepared from a dam2/dcm2 strain and were
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thus unmethylated. Overall, we detected no difference in Cas9
activity on adenine-methylated, cytosine-methylated, and un-
methylated target sequences. These results are consistent with
reports showing adenine methylation does not affect CRISPR-
mediated phage resistance in Streptococcus thermophilus [19] and
cytosine methylation does not affect SpCas9 activity on sequences
with CpG sites in human cells [20].
Figure 1. Native E. coli spacers target phage with modified DNA. In a BLASTn search, 1749 unique spacers from sequenced E. coli CRISPR
arrays were queried against T4-like phage genomes. (A) Spacer S641 matches 25 of 32 nucleotides in phage T2. The putative protospacer has a
permissible E. coli CRISPR PAM AAG and the matching nucleotides are concentrated at the 59 end as a seed sequence. The spacer originated from the
CRISPR1 locus of E. coli strain 579, a human-associated isolate from France. (B) Spacer S134 matches 29 of 32 nucleotides in phage CC31. While the
protospacer in phage CC31 has five nucleotides inserted in the center of the sequence, there are 15 exactly matched nucleotides at the 59 end in
addition to 14 matched nucleotides after the insertion. The PAM GAG and strongly matched seed region suggest it is a plausible E. coli CRISPR target.
This spacer was found in several strains, including E. coli C str. ATCC 8739, ECOR strains 17 through 21, one farm pig and two human fecal samples in
France, duck and cattle fecal samples in Australia [33], and enterotoxigenic E. coli (ETEC) strain UMNK88. The spacer and matching protospacer are in
blue, the transcribed CRISPR RNA (crRNA) in bold black, and PAM sequence in red.
doi:10.1371/journal.pone.0098811.g001
Figure 2. Cas9 cuts methylated cytosines and adenosines in E. coli. (A) Synthetic targets were designed to contain one to two dam (orange)
or dcm (blue) sites. A control unmethylated sequence (+) was included. The PAM sequence NGG for SpCas9 recognition is underlined. (B) In serial
transformations, we selected for the coexistence of DS-SPcas, the protospacer plasmid, and each spacer plasmid. The number of transformants was
divided by the number of colonies resulting from a control transformation using a spacer plasmid (-) that did not target the protospacer plasmid. This
relative number of transformants is plotted for E. coli K-12 and E. coli K-12 dam2/dcm2 from three independent experiments. Lines represent the
median.
doi:10.1371/journal.pone.0098811.g002
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Cas9 provides resistance against phages T7 and T4-like
RB49 with unmodified DNA
We next tested the ability of SpCas9 to provide resistance to
lytic phages without DNA modifications by constructing spacers
against phages T7 and RB49, neither of which contains modified
DNA. RB49 is a T4-like phage that is missing hydroxymethylase
and b-glucosyltransferase, which are required for modifying
cytosine to hmC and hmC to b-ghmC, respectively [21]. We
designed four spacers: two targeting the gene encoding the
primase/helicase enzyme of T7 (Figure 3A) and two targeting the
gene encoding the major capsid protein of RB49 (gp23), which is
one of the most conserved regions across T-even phages [21]
(Figure 3C). We transformed each spacer-encoding plasmid into
SpCas9-expressing E. coli K-12 MG1655 and E. coli B to create
strains protected from T7 and RB49 infection. We challenged
these strains with phage to calculate an efficiency of plating (EOP)
compared to unprotected strains; representative plaque plates are
included (Figures 3A and 3C).
In E. coli B, T7 had an EOP of 1023 on cells expressing spacer 1
or 2 relative to cells without spacers (Figure 3B). In E. coli K-12,
spacer 1 reduced sensitivity to T7 infection by four orders of
magnitude, though spacer 2 only lowered sensitivity by one order
of magnitude for unknown reasons. RB49 had an EOP of 1026 on
E. coli B with spacer 1 or 2, and an EOP of 1025 on E. coli K-12
with spacer 1 or 2 (Figure 3D). The decreased plaquing efficiencies
of T7 and RB49 on protected strains reflect Cas9 activity against
invading unmodified phage DNA.
Cas9 provides resistance against mutant phage T4 with
hmC DNA and wild-type T4 with ghmC DNA
Having established that Cas9 can confer resistance against non-
modified phage, we proceeded to challenge it with T4 phage
containing either hmC or ghmC DNA. During replication, wild-
type T4 synthesizes hmC, which contains a hydroxymethyl group
attached to the C5 position of cytosine, by using hydroxymethy-
lated dCTP serially converted from dCTP [22]. Then phage-
encoded glucosyltransferases add a glucose group to the hydro-
xymethyl group in a- or b-configuration [23] (Figure 4A). To
investigate Cas9 activity against T4 without glucosylated DNA, we
included mutant phage ‘‘T4 gt’’, which has hmC rather than
ghmC due to non-functional glucosyltransferases [16]. By using
restriction enzymes with varying sensitivity to modified cytosines
(according to REBASE, http://rebase.neb.com/), we confirmed
that our stocks of phage T4 had ghmC, phage T4 gt had hmC,
and phage RB49 did not have ghmC or hmC (Figure S1).
Figure 3. Cas9 reduces E. coli susceptibility to phages T7 and RB49. (A) Spacers against T7 were targeted against the primase/helicase gene
(gene 4A and 4B). The PAM is underlined in the sequence and shown as a black box in the diagram showing the orientation and location of the
protospacer (white box) on the gene. In a representative T7 plaque assay of protected and unprotected strains, there is substantial lysis on wild-type
(wt) E. coli K-12, visible plaquing on cells with spacer 2 (sp 2), and no plaques on cells with spacer 1 (sp 1). (B) The efficiency of plating of T7 was
calculated for each protected strain relative to the unprotected wild-type strain. Independent replicates of E. coli B (n = 4, 3, 3) and E. coli K-12 (n = 5, 5,
7) are plotted. Lines represent the median. (C) Spacers against RB49 were constructed against the major capsid protein (gp23). In a typical RB49
plaque assay, there is notable lysis on wild-type E. coli B, some plaques on cells with spacer 1, and a few plaques on cells protected with spacer 2. (D)
The efficiency of plating of RB49 was quantified for each protected strain relative to the unprotected wild-type strain. Shown are independent
replicates of E. coli B (n = 5, 3, 3) and E. coli K-12 (n = 3, 3, 3). Lines represent the median.
doi:10.1371/journal.pone.0098811.g003
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Since T4 gp23 is homologous to gp23 from RB49, we modified
our two spacers against RB49 to match the sequences of T4, and
also designed an additional spacer (Figure 4B). We tested these
spacers using efficiency-of-plating experiments as before; repre-
sentative plaque plates are shown (Figure 4C). Assays involving T4
gt used restriction-less E. coli K-12 because wild-type K-12 restricts
hmC DNA; the EOP of T4 gt on E. coli K-12 MG1655 is 1024
compared to T4 on MG1655 (Figure S2). In restriction-less E. coli
K-12, T4 gt exhibited an EOP of 1026 to 1025 on cells carrying
any one of the three spacers (Figure 4D). Wild-type T4 displayed
an EOP of 1025 on E. coli K-12 MG1655 with spacers 1 or 2, and
an EOP of 1023 on cells expressing spacer 3. On E. coli B with any
three spacers, T4 had an EOP of 1026 to 1024. As the difference
in EOP values for both T4 gt and wild-type T4 phages were
comparable to those of the non-modified T4-like phage RB49, our
results demonstrate that SpCas9 is not impeded by hydroxy-
methylation or glucosyl-hydroxymethylation of phage DNA.
Discussion
Our discovery that S. pyogenes Cas9 is insensitive to methylation,
hydroxymethylation, and glucosyl-hydroxymethylation renders it
unique among current genome-targeting technologies, as both
zinc-fingers (ZFs) and transcription activator-like (TAL) effectors
can be engineered to discriminate 5-methylcytosine from cytosine
[24,25]. This difference may be useful for biotechnological
applications.
In our bioinformatics search for candidate natural spacers, we
were only able to identify two possible sequences against T4-like
phages. This type of bioinformatics search is hampered by the
currently limited knowledge of specificity and tolerability of
mutations in both the acquisition and interference stages of
CRISPR systems. While this paper was under review, Fineran et
al. published a report exploring the robustness of the E. coli
CRISPR system, in which degenerate target regions with up to 13
mutations in the protospacer and PAM can promote ‘‘priming,’’ a
positive-feedback mechanism to incorporate new spacers based on
mutated or outdated spacers [26]. This suggests more lenient
bioinformatics searches would be allowable. Furthermore, our
search is limited by available sequences of E. coli and phages
known to modify their DNA, as well as the possibility that these
isolates do not encounter T4-like phages in their environments.
Future searches may provide additional evidence of CRISPR-
based immunity to DNA-modifying phages.
Interestingly, we observed that different spacers conferred
differing levels of resistance against phage infection. Since
mutations in the protospacer or PAM can allow phage to escape
[27,28], we sequenced Cas9-targeted regions of plaques that
appeared on protected strains. Indeed, T4 and T7 plaques on
protected E. coli had mutated one nucleotide in the PAM, or one
to two nucleotides in the protospacer (Table S1). Less effective
Figure 4. Cas9 reduces E. coli susceptibility to phages T4 and T4 gt. (A) The structures of cytosine and modified cytosines are shown. T4 gt
has 100% hydroxymethylated cytosines (hmCs). T4 has 100% glucosyl-hydroxymethylated cytosines (ghmCs), specifically 70% a- and 30% b-ghmCs.
The ghmC structure shown is in the b-configuration. (B) Spacers against T4 were also designed against the major capsid protein (gp23), which is
homologous to that of RB49. For comparison, the RB49 protospacers are aligned below in italics, where dots indicate identical nucleotides. In the T4
sequences, the PAM is underlined. The PAM (black box) and protospacer (white box) are represented on the gene. (C) In a typical plaque assay with
T4 gt (left plate), there was complete lysis on wild-type (wt) restriction-less (r-l) E. coli K-12 and few plaques on cells with spacers 1, 2, or 3 (sp 1, sp 2,
or sp 3). In an assay with T4 (right plate), there was complete lysis on wild-type E. coli K-12 MG1655, numerous plaques on cells with spacer 1 or 3, and
about a dozen on spacer 2. (D) The efficiency of plating of T4 and T4 gt was quantified for each protected strain relative to the unprotected wild-type
strain. Independent replicates of restriction-less E. coli K-12 (n = 5, 3, 3, 5), E. coli K-12 (n = 4, 4, 5, 6), and E. coli B (n = 5, 3, 3, 3) are plotted. Lines
represent the median.
doi:10.1371/journal.pone.0098811.g004
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spacers may be targeting sequences that are more readily mutated,
though we cannot rule out the non-mutually exclusive possibility
that Cas9 acts more slowly on certain sequences and thus allows
phage-induced lysis to outpace Cas9-enabled protection. In S.
thermophilus CRISPR1 and CRISPR3 systems, the uncut phage
genome can still be observed in bacteriophage-insensitive mutants
[29,30]. Further investigation of how some but not all phage DNA
molecules escape Cas9 cutting during phage infection is needed.
While phages may inactivate CRISPR proteins [31] or encode
their own CRISPR-Cas systems [32], we have demonstrated that
DNA modifications that normally circumvent bacterial restriction
systems do not impede Type II CRISPR systems. Our findings
may help explain why DNA modifications remain uncommon
among bacteriophages characterized to date whereas nearly half of
bacteria have CRISPR structures [8].
Supporting Information
Figure S1 Restriction digest of phages. Phage DNA was
extracted by using the Qiagen Blood and Tissue Kit on 200 mL of
phage stock. 10 or 20 U of each enzyme (1 mL) was added to 5 mL
of 10X CutSmart Buffer (NEB) in a 50 mL reaction volume
containing approximately 100 ng of phage RB49 or T4 DNA, or
800 ng of T4 gt DNA. The reactions were incubated at 37uC for
4 hours before visualizing on a 1% agarose gel stained with SYBR
Gold. As expected, DraI cuts all RB49, T4 gt, and T4; HpaII and
NheI are sensitive to methylated cytosines and only cut RB49; and
XbaI has 50% activity on hmC and partially cuts T4 gt. Blue text
denotes cutting.
(TIF)
Figure S2 Efficiency of plating of T4 gt on wild-type E.
coli K-12. Calculated relative to either T4 infecting E. coli K-12
or T4 gt infecting restriction-less E. coli K-12, phage T4 gt forms
plaques on E. coli K-12 at four orders of magnitude less efficiently
(red data points). As a general comparison of restriction-
modification versus Cas9-mediated protection, Cas9 provides
around an order of magnitude greater resistance to phage
infection on average, though the level of resistance varies by
sequence (blue data points). Independent replicates (n = 11, 5, 5, 5,
4, 15) are plotted; lines represent the median. Cas9+ data were
compiled from experiments with various spacer sequences as
described in the main text.
(TIF)
Table S1 Phage escapee analysis. We picked 13 plaques
that formed on Cas9-protected host E. coli strains and sequenced
the targeted region to identify any mutations. The PAM sequences
are underlined. Mutations are in bold text and double-underlined.
(DOCX)
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